Topical application of ozonated sunflower oil accelerates the healing of lesions of cutaneous leishmaniasis in mice under meglumine antimoniate treatment
Abstract Besides being scarce, the drugs available for treating cutaneous leishmaniasis have many adverse effects. Ozone is an option to enhance the standard treatment due to the wound-healing activity reported in the literature. In this study, we evaluated the efficiency of ozonated sunflower oil as an adjuvant in treating cutaneous lesions caused by Leishmania amazonensis. BALB/c mice were infected with L. amazonensis, and after the lesions appeared, they were treated in four different schedules using the drug treatment with meglumine antimoniate (Glucantime®), with or without ozonated oil. After thirty days of treatment, the lesions' thickness and their parasitic burden, blood leukocytes, production of NO and cytokines from peritoneal macrophages and lymph node cells were analyzed. The group treated with ozonated oil plus meglumine antimoniate showed the best performance, improving the lesion significantly. The parasitic burden showed that ozonated oil enhanced the leishmanicidal activity of the treatment, eliminating the parasites in the lesion. Besides, a decrease in the TNF levels from peritoneal macrophages and blood leukocytes demonstrated an immunomodulatory action of ozone in the ozonated oil-treated animals compared to the untreated group. Thus, ozonated sunflower oil therapy has been shown as an adjuvant in treating Leishmania lesions since this treatment enhanced the leishmanicidal and wound healing effects of meglumine antimoniate..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:213 |
|---|---|
| Enthalten in: |
Medical microbiology and immunology - 213(2024), 1 vom: 27. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pivotto, Ana Paula [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s00430-024-00788-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR055301479 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR055301479 | ||
| 003 | DE-627 | ||
| 005 | 20240327065005.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240327s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00430-024-00788-x |2 doi | |
| 035 | |a (DE-627)SPR055301479 | ||
| 035 | |a (SPR)s00430-024-00788-x-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 570 |a 610 |q VZ |
| 084 | |a 44.75 |2 bkl | ||
| 100 | 1 | |a Pivotto, Ana Paula |e verfasserin |0 (orcid)0000-0002-7238-4539 |4 aut | |
| 245 | 1 | 0 | |a Topical application of ozonated sunflower oil accelerates the healing of lesions of cutaneous leishmaniasis in mice under meglumine antimoniate treatment |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Abstract Besides being scarce, the drugs available for treating cutaneous leishmaniasis have many adverse effects. Ozone is an option to enhance the standard treatment due to the wound-healing activity reported in the literature. In this study, we evaluated the efficiency of ozonated sunflower oil as an adjuvant in treating cutaneous lesions caused by Leishmania amazonensis. BALB/c mice were infected with L. amazonensis, and after the lesions appeared, they were treated in four different schedules using the drug treatment with meglumine antimoniate (Glucantime®), with or without ozonated oil. After thirty days of treatment, the lesions' thickness and their parasitic burden, blood leukocytes, production of NO and cytokines from peritoneal macrophages and lymph node cells were analyzed. The group treated with ozonated oil plus meglumine antimoniate showed the best performance, improving the lesion significantly. The parasitic burden showed that ozonated oil enhanced the leishmanicidal activity of the treatment, eliminating the parasites in the lesion. Besides, a decrease in the TNF levels from peritoneal macrophages and blood leukocytes demonstrated an immunomodulatory action of ozone in the ozonated oil-treated animals compared to the untreated group. Thus, ozonated sunflower oil therapy has been shown as an adjuvant in treating Leishmania lesions since this treatment enhanced the leishmanicidal and wound healing effects of meglumine antimoniate. | ||
| 650 | 4 | |a Ozone therapy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Leishmanicidal |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a utaneous lesions |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Wound healing |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a de Souza Lima, Lucas Bonatto |0 (orcid)0000-0002-3676-6855 |4 aut | |
| 700 | 1 | |a Michelon, Alexandra |0 (orcid)0000-0002-0468-7394 |4 aut | |
| 700 | 1 | |a Ferreira, Camilla Zottesso Pellon |4 aut | |
| 700 | 1 | |a Gandra, Rinaldo Ferreira |0 (orcid)0000-0001-9586-7253 |4 aut | |
| 700 | 1 | |a Ayala, Thaís Soprani |0 (orcid)0000-0002-2080-2516 |4 aut | |
| 700 | 1 | |a Menolli, Rafael Andrade |0 (orcid)0000-0003-2728-8318 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medical microbiology and immunology |d Springer Berlin Heidelberg, 1886 |g 213(2024), 1 vom: 27. März |w (DE-627)SPR005738423 |w (DE-600)1462140-X |x 1432-1831 |7 nnns |
| 773 | 1 | 8 | |g volume:213 |g year:2024 |g number:1 |g day:27 |g month:03 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00430-024-00788-x |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.75 |q VZ |
| 951 | |a AR | ||
| 952 | |d 213 |j 2024 |e 1 |b 27 |c 03 | ||